Both products sucking but Praluent now leads Repatha. Praluent scripts decreased in the 62nd week of data, showing 2,966 scripts (vs. 3,109 in Week 61. For comparison, we also show scripts for AMGN's PCSK9, Repatha, which had 2,604 scripts in its 58th week of data (a decrease from 2,608 scripts seen in Week 57).
Lets assume the net cost of these drugs is 9k a year not 14k. Let's assume that each script is for one injection every two weeks meaning each script is $346. The total market of 6000 scripts a week means $2.08M for both drugs or $1M a week for each brand. That would mean each product is a $52M drug. If we assume each script is good for a whole month or $750 a script, that means each brand is only making $100M. $100M brand is far from being a blockbuster.
